Monico Luna

Monico Luna serves as a key procurement professional within the National Cancer Institute, supporting the agency’s mission to accelerate cancer research through advanced scientific instrumentation and diagnostic technologies. Responsible for managing complex acquisitions of analytical laboratory equipment and precision measurement systems, Luna facilitates the procurement of high-performance instruments critical to genomic analysis, molecular diagnostics, and translational research infrastructure. Their work directly enables NIH NCI’s strategic priorities by ensuring research laboratories have access to cutting-edge, FDA-cleared, and CLIA-compliant technologies essential for precision medicine initiatives. Luna maintains a consistent working relationship with Roche Diagnostics Corporation, a primary supplier of integrated diagnostic platforms, reagents, and automated laboratory systems. This partnership reflects a focus on vendor ecosystems capable of delivering scalable, validated, and interoperable analytical solutions aligned with NCI’s research workflows. The procurement pattern indicates a preference for established industry leaders with proven regulatory compliance, technical support capacity, and validated performance in high-throughput clinical and preclinical settings. There is no preference for socioeconomic set-asides, with 100% of acquisitions conducted under full and open competition. This reflects a mission-driven emphasis on technical capability and performance over socioeconomic criteria, prioritizing the highest-quality, most reliable solutions to support time-sensitive cancer research. Small business participation is not formally incentivized in this procurement portfolio, indicating a focus on technical superiority and operational continuity. Luna’s procurement activity is concentrated in NAICS 334516 (Analytical Laboratory Instrument Manufacturing) and 334519 (Other Measuring and Controlling Device Manufacturing), encompassing next-generation sequencers, mass spectrometers, flow cytometers, and automated liquid handling systems. Their expertise lies in acquiring complex, high-precision instruments requiring rigorous validation, calibration, and integration with data analytics platforms—ensuring that NCI’s research infrastructure remains at the forefront of oncology innovation.